A forum for researchers, students and applicants in the field of cyclodextrin technology
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
The 2,6-di-O-methyl-β-cyclodextrin (dMβCD) is an amphiphilic annular compound consisting of seven dimethylglucose molecules. This compound is well known as a
A Special issue “Drug-Cyclodextrin Interactions. A Basis for New Formulations” in Molecules (ISSN 1420-3049, http://www.mdpi.com/journal/molecules) will be published. Contributions of either an original research
The webinar held on Apr. 15-16, 2021 and organized by Cyclolab received wide attantion. It was in the afternoon Central
Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Lipid rafts are functional membrane microdomains containing sphingolipids, including gangliosides, and cholesterol. These regions are characterized by highly ordered and
A novel class of specifically engineered, dimerized cyclodextrin nanostructures was developed for the encapsulation of toxic biomolecules such as 7-ketocholesterol
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Therapies targeting neurological conditions such as Alzheimer’s or Parkinson’s diseases are hampered by the presence of the blood-brain barrier (BBB).
